Tag Archives: Doha Declaration

USTR issued 2012 Special 301 report

Posted on May 4, 2012 by

United States Trade Representative issued 301 report that reflects the Administration’s resolve to encourage and maintain effective IPR protection and enforcement worldwide. It identifies a wide range of concerns, including troubling “indigenous innovation” policies that may unfairly disadvantage U.S. rights … Continue reading →

Posted in Compulsory Licensing, data exclusivity, IPR Enforcement, Special 301 report, TRIPS plus | Tagged , , | Leave a comment

PhRMA’s Special 301 Comments on Indian Compulsory Licensing Misinterpret TRIPS Obligations

Posted on March 30, 2012 by

Source: Infojustice PhRMA’s Special 301 comments to the U.S. Trade Representative include a section on the compulsory licensing provisions in India’s Patents Act.  PhRMA recommends that “India should ensure that the CL provisions comply with TRIPS by… Eliminating price as a trigger to … Continue reading →

Posted in Compulsory Licensing, TRIPS, TRIPS flexibilities, WTO | Tagged , , | Leave a comment

Press Release: The Treatment Action Campaign (TAC) calls on government to amend South Africa’s Patents Act and protect our right to health

Posted on November 17, 2011 by

17_Nov-2011 (Cape Town) – Ten years ago this week, member countries of the World Trade Organisation (WTO) signed the Declaration on the TRIPS Agreement and Public Health (“the Doha Declaration”). Members were gathered in Doha to discuss valid concerns that … Continue reading →

Posted in Compulsory Licensing, Doha Declaration, Drug Pricing, Generic drug, South Africa's Patent Act, TRIPS, TRIPS plus | Tagged , , | Leave a comment

ACTA Faces Criticism at WTO and in the United States

Posted on November 8, 2011 by

Source: Bridges Weekly 3 November 2011 A nearly concluded multi-country agreement on counterfeiting came under fire at the WTO last week, as some members accused the deal, negotiated among a group of mostly industrialised country governments, of undermining multilateral cooperation … Continue reading →

Posted in ACTA, IPR Enforcement, TRIPS plus | Tagged , , | Leave a comment

Global Access Licensing as means to increase access to medicines

Posted on July 15, 2011 by

Read here an interesting blog article by UAEM suggesting Global Access Licensing as means for ensuring that public funded research on medical innovation reaches to people living in the developing countries on affordable prices. Global Access Licensing would allow generic … Continue reading →

Posted in Generic drug, HIV/Aids | Tagged , , , , , | Leave a comment

Your pills, your food, your doctor, your water…

Posted on November 18, 2010 by

… — they are all under attack. Every time you fall ill, America gets a little richer, for we are a billion dollar market by Mira Shiva, Public Health Activist In the past year America has seen the most violent, … Continue reading →

Posted in ACTA, EU-India FTA | Tagged , , , , , , , , , , | Leave a comment

Alexandra Heumber, MSF Access Campaign, giving a speech at the European Parliament

Posted on October 28, 2010 by

European Parliament, Brussels, 17. Febuary 2009 – Alexandra Heumber, IP Policy Adviser, MSF Access to Essential Medicines Campaign was giving a speech at the European Parliament on TRIPS plus provisions and Access to medicines in the current EU FTAs and … Continue reading →

Posted in EU-India FTA | Tagged , , , , , , , , , | Leave a comment